Last checked at 
1 Aug 2023 15:08
Syncona Limited
Result of Annual General Meeting
1 August 2023
At the Annual General Meeting of Syncona Limited (the "Company") held today, all Resolutions as set out in the 'Notice of the 2023 Annual General Meeting' dated 28 June 2023 sent to shareholders of the Company (the "Notice") were duly passed.
Resolutions 1 to 13 were proposed as Ordinary Resolutions. Resolution 14 was proposed as a Special Resolution and Resolution 15 was proposed as an Extraordinary Resolution.
Details of the proxy voting results, which should be read alongside the Notice, are noted below:
No | Resolution | For | Discretion | Against | Abstain (withheld) |
1 | Receive and consider the Annual Audited Financial Statements of the Company for the year ended 31 March 2023, together with the Reports of the Directors and Auditors therein | 509,248,042 (99.99%) | (0) (0%) | 9,810 (0.01%) | 3,726 |
2 | Re-appointment of Deloitte LLP (Guernsey Branch) as Auditors | 499,812,823 (99.99%) | (0) (0%) | 64,344 (0.01%) | 9,384,411
|
3 | Authorise the Directors to determine the remuneration of the Auditors | 499,860,699 (99.99%) | (0) (0%) | 16,468 (0.01%) | 9,384,411 |
4 | Re-elect Melanie Gee as a Director | 506,670,977 (99.49%) | (0) (0%) | 2,586,875 (0.51%) | 3,726 |
5 | Re-elect Julie Cherrington as a Director | 509,234,482 (99.99%) | (0) (0%) | 23,370 (0.01%) | 3,726 |
6 | Re-elect Cristina Csimma as a Director | 509,234,482 (99.99%) | (0) (0%) | 23,370 (0.01%) | 3,726 |
7 | Re-elect Virginia Holmes as a Director | 506,670,977 (99.49%) | (0) (0%) | 2,586,875 (0.51%) | 3,726 |
8 | Re-elect Robert Hutchinson as a Director | 506,636,608 (99.49%) | (0) (0%) | 2,616,589 (0.51%) | 8,381
|
9 | Re-elect Kemal Malik as a Director | 506,636,608 (99.49%) | (0) (0%) | 2,616,589 (0.51%) | 8,381
|
10 | Re-elect Gian Piero Reverberi as a Director | 506,636,608 (99.49%) | (0) (0%) | 2,616,589 (0.51%) | 8,381
|
11 | Approve the report on implementation of the Remuneration Policy for Non-Executive Directors | 509,148,250 (99.94%) | 211,077 (0.04%) | 93,843 (0.02%) | 14,961
|
12 | Approve the Company's Remuneration Policy | 509,149,180 (99.98%) | (0) (0%) | 101,934 (0.02%) | 10,464
|
13 | Authority to allot and issue shares, as set out in the Notice | 508,406,358 (99.83%) | (0) (0%) | 848,009 (0.17%) | 7,211
|
14 | Authorise the Company to purchase its own shares, as set out in the Notice | 507,133,706 (99.58%) | (0) (0%) | 2,124,146 (0.42%) | 3,726 |
15 | Disapply pre-emption rights, as set out in the Notice | 487,907,670 (98.37%) | (0) (0%) | 8,081,414 (1.63%) | 13,272,494
|
A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.
In accordance with the Listing Rule 9.6.2, a copy of all the resolutions passed other than resolutions concerning ordinary business have been submitted to the Financial Conduct Authority via the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The full text of the resolutions can be found in the Notice, which is available on the Company's website at https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/.
Enquiries
Syncona LimitedAnnabel Clark / Fergus Witt
Tel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
About Syncona:
Syncona's purpose is to invest to extend and enhance human life. We do this by creating and building companies to deliver transformational treatments to patients in areas of high unmet need.
Our strategy is to create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic areas, for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.